Summary

for people ages 18 years and up (full criteria)
at UCSD
study started
estimated completion:

Description

Summary

The purpose of this multicenter, Phase 1/2, open-label, study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).

Official Title

A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Keywords

Small Cell Lung Cancer Cancer Extensive-Stage Small Cell Lung Cancer Nivolumab Ipilimumab Rovalpituzumab tesirine Lung Neoplasms Small Cell Lung Carcinoma Antibodies, Monoclonal Rovalpituzumab Tesirine and nivolumab Rovalpituzumab Tesirine and nivolumab plus ipilimumab 1 mg/kg Rovalpituzumab Tesirine and nivolumab plus ipilimumab 3 mg/kg

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants with histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable disease
  • Eastern Cooperative Oncology Group (ECOG) 0-1
  • Adequate hematologic, hepatic, and renal function

You CAN'T join if...

  • Has active, known, or suspected autoimmune disease
  • Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug

Locations

  • Ucsd /Id# 161030
    La Jolla California 92037 United States
  • Oregon Health and Science University /ID# 161029
    Portland Oregon 97239-3098 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03026166
Phase
Phase 1
Study Type
Interventional
Last Updated